Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
08 2021
Historique:
revised: 09 04 2021
received: 19 01 2021
accepted: 23 05 2021
pubmed: 18 6 2021
medline: 29 10 2021
entrez: 17 6 2021
Statut: ppublish

Résumé

The prospective, multicentre Peripartum Cardiomyopathy in Nigeria (PEACE) registry originally demonstrated a high prevalence of peripartum cardiomyopathy (PPCM) among patients originating from Kano, North-West Nigeria. In a post hoc analysis, we sought to determine if this phenomenon was characterized by a differential case profile and outcome among PPCM cases originating elsewhere. Overall, 199 (81.6%) of a total 244 PPCM patients were recruited from three sites in Kano, compared with 45 patients (18.4%) from 11 widely dispersed centres across Nigeria. Presence and extent of ventricular myocardial remodelling during follow-up, relative to baseline status, were assessed by echocardiography. During median 17 months follow-up, Kano patients demonstrated significantly better myocardial reverse remodelling than patients from other sites. Overall, 50.6% of patients from Kano versus 28.6% from other regions were asymptomatic (P = 0.029) at study completion, with an accompanying difference in all-cause mortality (17.6% vs. 22.2% respectively, P = 0.523) not reaching statistical significance. Alternatively, 135/191 (84.9%) of Kano patients had selenium deficiency (<70 μg/L), and 46/135 (34.1%) of them received oral selenium supplementation. Critically, those that received selenium supplementation demonstrated better survival (6.5% vs. 21.2%; P = 0.025), but the supplement did not have significant impact on myocardial remodelling. This study has shown important non-racial regional disparities in the clinical features and outcomes of PPCM patients in Nigeria, that might partly be explained by selenium supplementation.

Identifiants

pubmed: 34137499
doi: 10.1002/ehf2.13463
pmc: PMC8318483
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3257-3267

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Mayo Clin Proc. 2005 Dec;80(12):1602-6
pubmed: 16342653
J Postgrad Med. 2002 Jul-Sep;48(3):206-8
pubmed: 12432198
J Am Coll Cardiol. 2005 Aug 2;46(3):497-504
pubmed: 16053964
Heart. 2013 Mar;99(5):308-13
pubmed: 23118348
N Engl J Med. 2002 Oct 31;347(18):1403-11
pubmed: 12409542
J Am Heart Assoc. 2017 Apr 3;6(4):
pubmed: 28373243
ESC Heart Fail. 2020 Feb;7(1):235-243
pubmed: 31990449
ESC Heart Fail. 2021 Aug;8(4):3257-3267
pubmed: 34137499
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Am Coll Cardiol. 2020 Nov 17;76(20):2352-2364
pubmed: 33183509
Trop Doct. 1995 Jul;25(3):118-23
pubmed: 7660481
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Am J Cardiol. 2006 Jun 15;97(12):1765-8
pubmed: 16765131
Circ J. 2011;75(8):1975-81
pubmed: 21617320
Eur J Heart Fail. 2019 Dec;21(12):1534-1542
pubmed: 31724271
Circ Heart Fail. 2016 Mar;9(3):e002683
pubmed: 26915373
Eur Heart J. 2020 Oct 14;41(39):3787-3797
pubmed: 32840318
Eur J Heart Fail. 2019 Jul;21(7):827-843
pubmed: 31243866
Heart Views. 2016 Apr-Jun;17(2):55-61
pubmed: 27512533
BMC Cardiovasc Disord. 2016 Jan 29;16:27
pubmed: 26821537
BMC Cardiovasc Disord. 2020 Oct 21;20(1):457
pubmed: 33087055
N Engl J Med. 1997 Feb 20;336(8):525-33
pubmed: 9036306
Int J Mol Sci. 2015 Apr 07;16(4):7644-54
pubmed: 25853263
J Am Coll Cardiol. 2015 Aug 25;66(8):905-14
pubmed: 26293760
Eur J Heart Fail. 2010 Aug;12(8):767-78
pubmed: 20675664

Auteurs

Kamilu M Karaye (KM)

Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria.
Department of Medicine, Bayero University, Kano, Nigeria.
Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
Hatter Institute for Cardiovascular Research in Africa & CHI, Cape Town, South Africa.

Naser A Ishaq (NA)

Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria.

Hadiza Sai'du (H)

Department of Medicine, Bayero University, Kano, Nigeria.
Department of Medicine, Murtala Mohammed Specialist Hospital, Kano, Nigeria.

Sulaiman A Balarabe (SA)

Department of Medicine, Muhammad Abdullahi Wase Specialist Hospital, Kano, Nigeria.

Bashir G Ahmed (BG)

Department of Medicine, Muhammad Abdullahi Wase Specialist Hospital, Kano, Nigeria.

Umar G Adamu (UG)

Department of Medicine, Federal Medical Centre, Bidda, Nigeria & Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Idris Y Mohammed (IY)

Department of Chemical Pathology, Aminu Kano Teaching Hospital, Medicine Bayero University, Kano, Nigeria.

Isa Oboirien (I)

Department of Medicine, Dalhatu Araf Specialist Hospital, Lafia, Nigeria.

Ejiroghene M Umuerri (EM)

Department of Medicine, Delta State University Teaching Hospital, Oghara, Nigeria.

Abaram C Mankwe (AC)

Department of Medicine, Federal medical centre, Yenagoa, Yenagoa, Nigeria.

Vincent Y Shidali (VY)

Department of Medicine, Federal Medical Center, Keffi, Nigeria.

Sotonye Dodiyi-Manuel (S)

Department of Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.

Paschal Njoku (P)

University of Nigeria Teaching Hospital, Enugu, Nigeria.

Taiwo Olunuga (T)

Department of Medicine, Federal Medical centre, Abeokuta, Nigeria.

Veronica Josephs (V)

Department of Medicine, University of Benin Teaching Hospital, Benin, Nigeria.

Amam C Mbakwem (AC)

Department of Medicine, University of Lagos, Lagos, Nigeria.

Okechukwu S Ogah (OS)

Department of Medicine, University College Hospital, Ibadan, Nigeria.

Jamilu Tukur (J)

Department of Obstetrics and Gynecology, Bayero University, Kano, Nigeria.

Basil Okeahialam (B)

Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria.

Simon Stewart (S)

Torrens University Australia, Adelaide, South Australia, Australia.

Michael Henein (M)

Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.

Karen Sliwa (K)

Hatter Institute for Cardiovascular Research in Africa & CHI, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH